Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Q: What does this research mean for the field?

Real-world use of a commercially available immunoglobulin-based ctDNA assay demonstrates that detectable post-treatment measurable residual disease (MRD) is associated with significantly lower 12-month progression-free survival in patients with large B-cell lymphoma. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Patrick Gould; Devyn Coskey; Xin Ma; Shikun Wang; Sonia Godbole; David Bond; Andrew Ip; Snegha Ananth; Shaunak Varma; Emily Ayers; Rachel Faden; Cassandra Gillespie; Basem William; Ryan Jacobs; Bei Hu; Jake Lattin; David Russler-Germain; Michele Stanchina; Ashley Rose; Michael Randall; Michael Spinner; Vidiya Srikakulapu; Praveen Ramakrishnan Geethakumari; Alan Skarbnik; David W. Chitty; Mazie Tsang; Cassandra Duarte; Ajay Major; Allison M. Bock; Kelsey Baron; Brian Hess; Seda Tolu; Barbara Pro; Supriya Vaidya; Jennifer E. Amengual; Ran Reshef; Hua‐Jay J. Cherng

doi:10.3324/haematol.2026.300901

Key Points

To assess the real-world feasibility and prognostic value of circulating tumor DNA measurable residual disease (ctDNA-MRD) testing in patients with large B-cell lymphoma after treatment.
Multicenter, retrospective study evaluating real-time post-treatment ctDNA-MRD using a commercial immunoglobulin rearrangement-targeted next-generation sequencing assay.
Included patients with large B-cell lymphoma evaluated after frontline immunochemotherapy (N=102) or chimeric antigen receptor (CAR) T-cell therapy.
The median turnaround time from blood sample collection to ctDNA-MRD test result was 9 days.
Following frontline therapy (N=102), detectable ctDNA-MRD was associated with significantly worse 12-month progression-free survival compared to undetectable ctDNA-MRD (15% vs. 85%, HR 14.5).

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Multicenter retrospective study reveals that detectable post-treatment ctDNA predicts disease progression in large B-cell lymphoma, indicating its utility for real-world monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gould et al. (2026) studied this question.

synapsesocial.com/papers/6a81796af2fb91fc834ac7f5 https://doi.org/10.3324/haematol.2026.300901

View Full Paper

Ask AI

Bookmark

Share

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Haematologica

Keep reading

More related papers

More from Haematologica